Back to top

MannKind reports ‘positive’ Phase 1b INFLO-1 results

MannKind (MNKD) announced positive topline results from INFLO-1, its Phase 1b randomized, double-blind, placebo-controlled study evaluating ninteda...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MannKind Corporation (MNKD)